Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Formula attenuates 99% of 365 coronaviruses in computer models
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Subscribe To Our Newsletter & Stay Updated
